dcSSc patients with recently active skin disease have a similar or even lower likelihood to show further progression of skin fibrosis in a 12 months trial – most likely because they have reached their peak skin score already. Recently active skin disease should not be used as an enrichment criterion in clinical trials targeting skin fibrosis
ACTIVE SKIN DISEASE AT BASELINE DOES NOT PREDICT PROGRESSION OF SKIN FIBROSIS AT ONE YEAR FOLLOW UP – A EUSTAR ANALYSIS / Dobrota, R. C.; Maurer, B.; Graf, N.; Kowal Bielecka, O.; Matucci Cerinic, M.; Airò, P.; Caramaschi, P.; Carreira, P.; Riemekasten, G.; Rosato, Edoardo; Allanore, Y.; Distler, O.. - In: ANNALS OF THE RHEUMATIC DISEASES. - ISSN 0003-4967. - STAMPA. - (2016), pp. 756-757. (Intervento presentato al convegno EULAR 2016 tenutosi a Londra) [10.1136/annrheumdis-2016-eular.5450].
ACTIVE SKIN DISEASE AT BASELINE DOES NOT PREDICT PROGRESSION OF SKIN FIBROSIS AT ONE YEAR FOLLOW UP – A EUSTAR ANALYSIS
ROSATO, Edoardo;
2016
Abstract
dcSSc patients with recently active skin disease have a similar or even lower likelihood to show further progression of skin fibrosis in a 12 months trial – most likely because they have reached their peak skin score already. Recently active skin disease should not be used as an enrichment criterion in clinical trials targeting skin fibrosis| File | Dimensione | Formato | |
|---|---|---|---|
|
Dobrota_active-skin_2016pdf
solo gestori archivio
Tipologia:
Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
128.67 kB
Formato
Adobe PDF
|
128.67 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
